ES2056854T3 - Tiadiazinonas. - Google Patents

Tiadiazinonas.

Info

Publication number
ES2056854T3
ES2056854T3 ES88108308T ES88108308T ES2056854T3 ES 2056854 T3 ES2056854 T3 ES 2056854T3 ES 88108308 T ES88108308 T ES 88108308T ES 88108308 T ES88108308 T ES 88108308T ES 2056854 T3 ES2056854 T3 ES 2056854T3
Authority
ES
Spain
Prior art keywords
tiadiazinonas
tiadiazinones
formula
treatment
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88108308T
Other languages
English (en)
Inventor
Rochus Dr Jonas
Jaime Dr Piulats
Inge Dr Lues
Michael Dr Klockow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19873719031 external-priority patent/DE3719031A1/de
Priority claimed from DE19873744149 external-priority patent/DE3744149A1/de
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2056854T3 publication Critical patent/ES2056854T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

LAS TIADIAZINONAS DE FORMULA (I) DONDE A, R1 A R6 Y Z TIENEN EL SIGNIFICADO QUE SE INDICA EN LA REIVINDICACION DE PATENTE I, POSEEN ACTIVIDADES POSITIVAS Y RESULTAN ADECUADAS PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES.
ES88108308T 1987-06-06 1988-05-25 Tiadiazinonas. Expired - Lifetime ES2056854T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873719031 DE3719031A1 (de) 1987-06-06 1987-06-06 5-(1,2,3,4-tetrahydrochinolyl)-3,6-dihydro-1,3,4-thiadiazin-2-one
DE19873744149 DE3744149A1 (de) 1987-12-24 1987-12-24 5-(2,3,4,5-tetrahydro-1h-1-benzazepinyl) -3,6-dihydro-1,3,4-thiadiazin-2-one

Publications (1)

Publication Number Publication Date
ES2056854T3 true ES2056854T3 (es) 1994-10-16

Family

ID=25856391

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88108308T Expired - Lifetime ES2056854T3 (es) 1987-06-06 1988-05-25 Tiadiazinonas.

Country Status (11)

Country Link
US (1) US4916128A (es)
EP (1) EP0294647B1 (es)
JP (1) JP2694535B2 (es)
KR (1) KR970000953B1 (es)
AU (1) AU614965B2 (es)
CA (1) CA1340362C (es)
DE (1) DE3882444D1 (es)
ES (1) ES2056854T3 (es)
HK (1) HK43096A (es)
HU (1) HU207068B (es)
IE (1) IE62113B1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901836D0 (en) * 1989-01-27 1989-03-15 Sobio Lab Compounds
DE4041074A1 (de) * 1990-12-21 1992-06-25 Merck Patent Gmbh Thiadiazinonderivate
DE4129062A1 (de) * 1991-09-02 1993-03-04 Merck Patent Gmbh Verfahren zur enantiomerentrennung von 5-hetaryl-1,3,4-thiadiazinonen
DE4134893A1 (de) * 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
TW218875B (es) * 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US5462934A (en) * 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
DE4223537A1 (de) * 1992-07-17 1994-01-20 Merck Patent Gmbh Thiadiazinone
ES2199251T3 (es) 1994-06-15 2004-02-16 Otsuka Pharmaceutical Company, Limited Derivados benzoheterociclicos utilizables como moduladores de vasopresina o de oxitocina.
DE19500558A1 (de) * 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DE19929785A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
US20030153585A1 (en) * 2000-01-13 2003-08-14 Sven-Alexander Schreder Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
WO2003060078A2 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7323455B2 (en) 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2628570A1 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2058308A1 (fr) * 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3172252D1 (en) * 1980-11-14 1985-10-17 Ici Plc Heterocyclic compounds
CA1199027A (en) * 1981-11-12 1986-01-07 Stuart D. Mills Heterocyclic derivatives of pyridazinone, thiadiazinone, oxadiazinone and triazinone
JPS61106574A (ja) * 1984-10-29 1986-05-24 Yoshitomi Pharmaceut Ind Ltd オキサ（またはチア）ジアジン誘導体
EP0303418A3 (en) * 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds

Also Published As

Publication number Publication date
EP0294647B1 (de) 1993-07-21
EP0294647A3 (en) 1989-07-05
IE881677L (en) 1988-12-06
AU614965B2 (en) 1991-09-19
KR890000475A (ko) 1989-03-14
US4916128A (en) 1990-04-10
JPS63310886A (ja) 1988-12-19
EP0294647A2 (de) 1988-12-14
HU207068B (en) 1993-03-01
JP2694535B2 (ja) 1997-12-24
AU1664688A (en) 1988-12-08
HK43096A (en) 1996-03-22
DE3882444D1 (de) 1993-08-26
CA1340362C (en) 1999-02-02
KR970000953B1 (ko) 1997-01-21
IE62113B1 (en) 1994-12-14
HUT51272A (en) 1990-04-28

Similar Documents

Publication Publication Date Title
ES2056854T3 (es) Tiadiazinonas.
IT7849523A0 (it) 3-1h-tetrazol-5-il-4h-pirido 1,2-a pirimidin-4-oni sostituiti utili in particolare come agenti terapeutici per inibire le reazioni allergiche e procedimento per la produzione dei detti derivati
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
BR9910251A (pt) Estimulação hematopoiética
ATE96313T1 (de) Fettsaeure-zusammensetzungen.
DK214978A (da) Hydroxyalkylphenoner og anvendelse deraf som fotosensibilisatorer
DK1056452T3 (da) Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
IT8348746A0 (it) Derivati amminometil-benzenici arilsostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni che li contengono
DK0424028T3 (da) S(+)-ibuprofen-L-aminosyre og S(+)-ibuprofen-D-aminosyre som et forbedret smertestillende middel med fremskyndet indtrædelse
DE59007288D1 (de) Verwendung des Wirkstoffs Azelastin und Glycerinethern zur Bekämpfung von Psoriasis-Erkrankungen.
ATE16489T1 (de) Aroylimidazolone.
IT8348747A0 (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
ES2068935T3 (es) Piridazinonas con actividad insecticida y acaricida y composiciones que las contienen.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE3586281D1 (de) Antisaeurezusammensetzung.
TR20150A (tr) Tiyazoli'sinamik asit nitrilleri bunlarin imalati ve pestitler o'arak kullanilmalari
IT7921922A0 (it) Procedimento per la determinazione dell'attivita' della colinesterasi e derivati della colina che vengono impiegati nel procedimento.
DK137589D0 (da) Salicylsyreholdigt middel til behandling af hudsygdomme
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
MX9202366A (es) Nuevas 2-amino-5-ciano-1,4-di hidro piridinas y procedimiento para su fabricacion.
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ATE51229T1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
DK0505400T3 (da) N-substituerede naphthalimider, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 294647

Country of ref document: ES